# Camurus

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/camurus).

## Overview

Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus creates new drug products with best-in-class potential, particularly in the areas of CNS, endocrinology, and oncology. The company operates across Europe, the US, and Australia, and is listed on Nasdaq Stockholm under the ticker CAMX. Camurus is committed to improving patient outcomes through its extensive R&D pipeline and strategic partnerships.

## Products & services

• Buvidal® for opioid dependence
• Brixadi® for opioid use disorder
• Oczyesa® for acromegaly
• CAM2029 for acromegaly and neuroendocrine tumors
• CAM2056 for obesity and diabetes
• FluidCrystal® drug delivery technology

- **Opioid Dependence Treatments** (50%) — Includes products like Buvidal® and Brixadi® for treating opioid use disorders.
- **Endocrinology Treatments** (25%) — Covers products like Oczyesa® for acromegaly and CAM2029 for endocrine disorders.
- **Oncology Treatments** (10%) — Includes pipeline products for cancer treatment.
- **Obesity and Diabetes Treatments** (10%) — Involves products like CAM2056 for obesity and diabetes management.
- **Drug Delivery Technology** (5%) — FluidCrystal® technology used for drug delivery solutions.

- Buvidal® for opioid dependence
- Brixadi® for opioid use disorder
- Oczyesa® for acromegaly
- CAM2029 for acromegaly and neuroendocrine tumors
- CAM2056 for obesity and diabetes
- FluidCrystal® drug delivery technology

## Customers

Camurus serves a diverse range of customers, primarily healthcare providers and pharmaceutical companies. Its products are used by medical professionals treating patients with severe and chronic conditions such as opioid dependence, acromegaly, and other endocrine disorders. The company also collaborates with pharmaceutical companies for the development and distribution of its products. Additionally, Camurus engages with patient advocacy groups and medical experts to support market entry and product adoption.

- **Healthcare Providers** (primary) — Purchase products like Buvidal® for treating opioid dependence.
- **Pharmaceutical Companies** (secondary) — Collaborate on product development and distribution.
- **Endocrinologists** (secondary) — Use products like Oczyesa® for treating endocrine disorders.
- **Patient Advocacy Groups** (emerging) — Support treatment adoption and market entry.

- Healthcare providers treating opioid dependence with Buvidal® and Brixadi®
- Endocrinologists using Oczyesa® for acromegaly treatment
- Pharmaceutical companies partnering for product development and distribution
- Patient advocacy groups supporting treatment adoption
- Medical experts collaborating on clinical data dissemination

## Geography

Camurus operates internationally with a strong presence in Europe, the US, and Australia. The company's headquarters are located in Lund, Sweden. Europe is a key market, particularly for products like Buvidal® and Oczyesa®, with significant sales in countries like Germany and Sweden. The US market is critical for the launch of new products such as Brixadi®. The company's global operations are supported by strategic partnerships and collaborations to expand its market reach.

- **Europe** (50%) — Key market for Buvidal® and Oczyesa®
- **North America** (30%) — Critical for Brixadi®
- **Australia** (20%) — Significant market for opioid dependence treatments

- Headquartered in Lund, Sweden
- Strong presence in Europe, US, and Australia
- Key markets include Germany and Sweden for Buvidal® and Oczyesa®
- US market critical for Brixadi® launch
- Global operations supported by strategic partnerships

## Strategy

Camurus focuses on expanding its product portfolio and global market presence through strategic partnerships and innovative R&D. The company aims to leverage its FluidCrystal® technology to develop long-acting medications that improve patient outcomes. Key strategic priorities include the successful launch of new products like Oczyesa® in Europe and Brixadi® in the US. Camurus also seeks to enhance its R&D pipeline with promising candidates like CAM2056 for obesity and diabetes. The company is committed to sustainable profitability and value creation for stakeholders.

- **Expand Product Portfolio** (medium-term) — To increase market reach and diversify offerings.
- **Leverage FluidCrystal® Technology** (long-term) — To develop innovative long-acting medications.
- **Successful Product Launches** (short-term) — To capture market share and drive revenue growth.

- Expand product portfolio through strategic partnerships
- Leverage FluidCrystal® technology for innovative drug development
- Focus on successful launch of Oczyesa® in Europe and Brixadi® in the US
- Enhance R&D pipeline with candidates like CAM2056
- Commit to sustainable profitability and stakeholder value creation

## Risks

Camurus faces several business and financial risks, including regulatory risks related to the approval of new drugs and changes in distribution models. Currency fluctuations pose a risk due to the company's international operations. There are also risks associated with R&D, such as clinical trial failures or delays. Additionally, competitive pressures from other pharmaceutical companies and potential IP disputes could impact market position. The company must also manage risks related to strategic partnerships and their execution.

- **Regulatory Approval Delays** [high] — Could delay market entry and revenue generation.
- **Currency Fluctuations** [medium] — Affect financial performance due to international operations.
- **R&D Failures** [critical] — Could result in sunk costs and lost opportunities.

- Regulatory risks in drug approval processes
- Currency fluctuations affecting international operations
- R&D risks including clinical trial failures or delays
- Competitive pressures from other pharmaceutical companies
- Potential IP disputes impacting market position
- Risks related to strategic partnership execution

## Accounting

Camurus' financial statements are prepared in accordance with IFRS, with critical accounting matters including revenue recognition from licensing agreements and milestone payments. The company faces currency risk due to its international operations, impacting reported revenues and expenses. Share-based payment programs also affect financial results, with costs recognized over the vesting period. Fair value measurements for financial instruments are based on observable market data, minimizing estimation risk. The company must carefully manage estimates and provisions, particularly in R&D and deferred tax assets.

- **Revenue Recognition** — high
- **Currency Risk** — medium
- **Share-Based Payments** — medium

- Revenue recognition from licensing agreements and milestone payments
- Currency risk impacting reported revenues and expenses
- Share-based payment programs affecting financial results
- Fair value measurements based on observable market data
- Management of estimates and provisions in R&D and deferred tax assets

---

*Last updated: 2026-08-11T04:04:51.429658+00:00*